With cardiovascular disease costing the NHS billions each year,1 PCSK9 inhibitors are a modern class of drug which can lower LDL-C by as much as 60-70%,2 that offer a practical solution to help tackle this problem.
This short video explores the clinical data surrounding the use of Praluent, the flexible dosing options and the Reflex pre-filled pen.
Abbreviations
LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9
References
- NHS England. Improving lipid management to reduce cardiovascular disease and save lives. 2023. Available at: https://www.england.nhs.uk/long-read/improving-lipid-management-to-reduce-cardiovascular-disease-and-save-lives/ [accessed November 2026]
- Stein EA et al. N Engl J Med 2012;366:1108–1118
